(19)
(11) EP 3 277 721 A1

(12)

(43) Date of publication:
07.02.2018 Bulletin 2018/06

(21) Application number: 16713273.7

(22) Date of filing: 24.03.2016
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 37/00(2006.01)
C07K 16/46(2006.01)
A61K 39/00(2006.01)
(86) International application number:
PCT/US2016/023902
(87) International publication number:
WO 2016/160476 (06.10.2016 Gazette 2016/40)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 03.04.2015 US 201562142706 P

(71) Applicant: Eli Lilly and Company
Indianapolis, IN 46285 (US)

(72) Inventors:
  • ALLAN, Barrett
    Indianapolis, Indiana 46206-6288 (US)
  • KIKLY, Kristine Kay
    Indianapolis, Indiana 46206-6288 (US)
  • WITCHER, Derrick Ryan
    Indianapolis, Indiana 46206-6288 (US)

(74) Representative: Kent, Lindsey Ruth 
Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road
Windlesham Surrey GU20 6PH
Windlesham Surrey GU20 6PH (GB)

   


(54) ANTI-CD20- / ANTI-BAFF BISPECIFIC ANTIBODIES